Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Polatuzumab Vedotin-Piiq in High grade B-cell lymphoma: ACTRN12626000586314 Clinical Landscape Report 2026
16 September 2026
ACTRN12626000586314 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
TELOMIR-1 in Metastatic Triple-Negative Breast Carcinoma: NCT07581314 Clinical Landscape Report 2026
16 September 2026
NCT07581314 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Dual CAR Dual KO NK Cells (The University of Texas MD Anderson Cancer Center) in Recurrent Glioblastoma: NCT07579208 Clinical Landscape Report 2026
16 September 2026
NCT07579208 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Finerenone in Metabolic Dysfunction Associated Steatohepatitis: NCT07585526 Clinical Landscape Report 2026
16 September 2026
NCT07585526 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
RLY-8161 in NRAS Mutant Melanoma: NCT07584226 Clinical Landscape Report 2026
16 September 2026
NCT07584226 clinical landscape for NRAS Mutant Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CS08399 in Locally Advanced Malignant Solid Neoplasm: NCT07583771 Clinical Landscape Report 2026
16 September 2026
NCT07583771 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
SENL-103 in Multiple Sclerosis, Primary Progressive: NCT07587125 Clinical Landscape Report 2026
16 September 2026
NCT07587125 clinical landscape for Multiple Sclerosis, Primary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
LVIVO-TaVec400 in Myasthenia Gravis: NCT07583030 Clinical Landscape Report 2026
16 September 2026
NCT07583030 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cadonilimab in Melanoma, Cutaneous Malignant: NCT07586904 Clinical Landscape Report 2026
16 September 2026
NCT07586904 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Universal allogeneic anti-CD19/BCMA CAR T-cells(The Children's Hospital of Zhejiang University School of Medicine) in Granulomatosis With Polyangiitis: NCT07586267 Clinical Landscape Report 2026
16 September 2026
NCT07586267 clinical landscape for Granulomatosis With Polyangiitis: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
REGN4336 in Renal Cell Carcinoma: NCT07594106 Clinical Landscape Report 2026
16 September 2026
NCT07594106 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MTM-H-001 in Myasthenia Gravis: NCT07593911 Clinical Landscape Report 2026
16 September 2026
NCT07593911 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.